GB2330533B - Composition for enhanced uptake of polar drugs from mucosal surfaces - Google Patents
Composition for enhanced uptake of polar drugs from mucosal surfacesInfo
- Publication number
- GB2330533B GB2330533B GB9900050A GB9900050A GB2330533B GB 2330533 B GB2330533 B GB 2330533B GB 9900050 A GB9900050 A GB 9900050A GB 9900050 A GB9900050 A GB 9900050A GB 2330533 B GB2330533 B GB 2330533B
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- mucosal surfaces
- enhanced uptake
- polar drugs
- polar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9614235.1A GB9614235D0 (en) | 1996-07-06 | 1996-07-06 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
| PCT/GB1997/001852 WO1998001159A2 (en) | 1996-07-06 | 1997-07-07 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9900050D0 GB9900050D0 (en) | 1999-02-24 |
| GB2330533A GB2330533A (en) | 1999-04-28 |
| GB2330533B true GB2330533B (en) | 2000-10-25 |
Family
ID=10796483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB9614235.1A Pending GB9614235D0 (en) | 1996-07-06 | 1996-07-06 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
| GB9900050A Expired - Fee Related GB2330533B (en) | 1996-07-06 | 1997-07-07 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB9614235.1A Pending GB9614235D0 (en) | 1996-07-06 | 1996-07-06 | Composition for enhanced uptake of polar drugs from mucosal surfaces |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0993305A2 (en) |
| JP (1) | JP2000515503A (en) |
| KR (1) | KR20000023583A (en) |
| AU (1) | AU722724B2 (en) |
| CA (1) | CA2257563A1 (en) |
| GB (2) | GB9614235D0 (en) |
| NO (1) | NO985956D0 (en) |
| WO (1) | WO1998001159A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6572874B1 (en) * | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
| EP1154761B1 (en) * | 1999-02-22 | 2008-02-20 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
| US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| JP2006510656A (en) * | 2002-12-11 | 2006-03-30 | チョン・クン・ダン・ファーマシューティカル・コーポレーション | Oral preparations of polar drugs that are difficult to absorb |
| DE102004027924A1 (en) * | 2004-06-09 | 2005-12-29 | Röhm GmbH & Co. KG | Pharmaceutical form containing the active ingredient cholylsarcosine |
| MX2008012678A (en) | 2006-04-07 | 2008-12-17 | Merrion Res Iii Ltd | Solid oral dosage form containing an enhancer. |
| KR20110007242A (en) | 2008-05-07 | 2011-01-21 | 메리온 리서치 Ⅲ 리미티드 | Compositions of peptides and processes of preparation thereof |
| MX343193B (en) | 2009-06-18 | 2016-10-26 | Allergan Inc | Safe desmopressin administration. |
| US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| CN103476419A (en) | 2011-01-07 | 2013-12-25 | 梅里翁第三研究有限公司 | Pharmaceutical compositions of iron for oral administration |
| ES2975708T3 (en) | 2015-01-29 | 2024-07-12 | Novo Nordisk As | Tablets comprising GLP-1 agonist and enteric coating |
| CN108201531A (en) * | 2016-12-19 | 2018-06-26 | 湖南尔康湘药制药有限公司 | Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007923A1 (en) * | 1989-01-19 | 1990-07-26 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| DE4222647A1 (en) * | 1991-07-15 | 1993-01-21 | Sandoz Ag | PEPTIDE PREPARATIONS |
| WO1995001183A1 (en) * | 1993-06-29 | 1995-01-12 | Ferring B.V. | Compositions for nasal administration of desmopressin |
| WO1997006813A1 (en) * | 1995-08-15 | 1997-02-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Mucosal preparation containing physiologically active peptide |
-
1996
- 1996-07-06 GB GBGB9614235.1A patent/GB9614235D0/en active Pending
-
1997
- 1997-07-07 EP EP97930663A patent/EP0993305A2/en not_active Withdrawn
- 1997-07-07 AU AU34539/97A patent/AU722724B2/en not_active Ceased
- 1997-07-07 WO PCT/GB1997/001852 patent/WO1998001159A2/en not_active Application Discontinuation
- 1997-07-07 JP JP10504949A patent/JP2000515503A/en active Pending
- 1997-07-07 CA CA002257563A patent/CA2257563A1/en not_active Abandoned
- 1997-07-07 GB GB9900050A patent/GB2330533B/en not_active Expired - Fee Related
-
1998
- 1998-12-18 NO NO985956A patent/NO985956D0/en not_active Application Discontinuation
-
1999
- 1999-01-06 KR KR1019997000028A patent/KR20000023583A/en not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007923A1 (en) * | 1989-01-19 | 1990-07-26 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| DE4222647A1 (en) * | 1991-07-15 | 1993-01-21 | Sandoz Ag | PEPTIDE PREPARATIONS |
| WO1995001183A1 (en) * | 1993-06-29 | 1995-01-12 | Ferring B.V. | Compositions for nasal administration of desmopressin |
| WO1997006813A1 (en) * | 1995-08-15 | 1997-02-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Mucosal preparation containing physiologically active peptide |
Non-Patent Citations (11)
| Title |
|---|
| Chemical Abstract à 112:42406 & Congr. Int. Technol. Pharm.,1989, 1, 91-98 (NAGAI et al.), * |
| Chemical Abstract à 95:109081 & Life Sci., 1981, 29(8), 803-809, (ZIV et al.) * |
| Chemical Abstract à 98:191258 & Biochem. Pharmacol., 1983, 32(5), 773-776 (ZIV et al.) * |
| Int. J. Pharm., 1991, 74(2-3), 95-103, (UCHIDA et al.) "Influence of Bile....Derivatives". * |
| J. Controlled Release, 1997, 46(1/02), 17-30 (KRAMER et al.)"Modified Bile.....Peptides and Drugs". * |
| J. Pharm. Sci., 1987, 76(5), 351-355, (LONGENECKER et al.) "Effects of ....Insulin in Sheep". * |
| J. Pharm. Sci., 1994, 83(10), 1465-1469, (SCOTT-MONCRIEFF etal.) "Enhancement...Micelles in Dogs". * |
| J. Pharmacobio-Dyn., 1988, 11(6), 395-401, (NAKADA et al.) "The Effect of Additives....in Rats". * |
| J. Pharmacobio-Dyn., 1989, 12(12), 736-743, (NAKADA et al.) "The Effect of Bile..Calcitonin in Rats" * |
| J. Pharmacol. Exp. Ther., 1988, 244(1), 23-28,(AUNGST et al)"Comparison...Absorption Promoter". * |
| Proc. Natl. Acad. Sci. USA, 1985, 82(21), 7419-7423 (GORDON et al.), "Nasal....Bile Salts". * |
Also Published As
| Publication number | Publication date |
|---|---|
| NO985956L (en) | 1998-12-18 |
| GB9614235D0 (en) | 1996-09-04 |
| JP2000515503A (en) | 2000-11-21 |
| AU722724B2 (en) | 2000-08-10 |
| EP0993305A2 (en) | 2000-04-19 |
| CA2257563A1 (en) | 1998-01-15 |
| GB2330533A (en) | 1999-04-28 |
| KR20000023583A (en) | 2000-04-25 |
| NO985956D0 (en) | 1998-12-18 |
| WO1998001159A2 (en) | 1998-01-15 |
| GB9900050D0 (en) | 1999-02-24 |
| WO1998001159A3 (en) | 1998-03-26 |
| AU3453997A (en) | 1998-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1025904A1 (en) | Pharmaceutical composition for combination of piperidinoalkanol-decongestant | |
| IL181059A0 (en) | Pharmaceutical compositions containing isoflavones | |
| GB9600426D0 (en) | Compositions | |
| EG24118A (en) | Pharmaceutical compositions | |
| IL127684A0 (en) | Composition for appetite suppression | |
| GB2330533B (en) | Composition for enhanced uptake of polar drugs from mucosal surfaces | |
| GB9616672D0 (en) | Pharmaceutical compositions | |
| ZA9710006B (en) | Novel pharmaceutical compositions | |
| GB9610359D0 (en) | Pharmaceutical compositions | |
| GB9622681D0 (en) | Pharmaceutical compositions | |
| KR100207900B1 (en) | Dielectric ceramic composition | |
| GB9606429D0 (en) | Pharmaceutical compositions | |
| SG50003A1 (en) | Dielectric ceramics composition | |
| PL337804A1 (en) | Solubilised compositions of sertralin | |
| GB9613457D0 (en) | Pharmaceutical compositions | |
| GB9623962D0 (en) | Pharmaceutical composition | |
| GB9618376D0 (en) | Pharmaceutical compositions | |
| GB9618964D0 (en) | Oral composition | |
| GB9610136D0 (en) | Pharmaceutical compositions | |
| GB9614188D0 (en) | Ceramic compositions | |
| HUP0003528A3 (en) | Pharmaceutical compositions containing dihydropolyprenols | |
| EP0906085A4 (en) | Compositions | |
| SI0941095T1 (en) | Improved pharmaceutical compositions | |
| GB9606586D0 (en) | Pharmaceutical compositions | |
| GB9603942D0 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20020707 |